We are #2 because we put KIDS FIRST
This technology utilizes methods and compositions related to reducing the risk of or preventing fetal wastage by administering CXCR3 inhibitors.
IRAK1 is a drugable target for treatment of MDS, and IRAK1/BCL2 inhibitors synergistically co-treat MDS.
A Growing Pipeline of Innovations
Find out how we are building the research-to-market bridge in the latest Research Horizons
Partner with Us
View our innovation portfolio
Seminar with Industry:
September 19, 2018
Mike Myers , Senior Director Lilly Research Labs
Seminar with Inventor:
October 18, 2018
Ryan Moore, MD, Assistant Professor Cardiology